Objective: There is an evidence gap regarding the predictive accuracy of the triglycerideglucose (TyG) index for long-term major adverse cardiovascular events (MACEs) in individuals with high cardiovascular risk. The aim of this investigation was to evaluate the predictive value of the TyG index for long-term MACEs in patients at high cardiovascular risk. Methods: In total, 483 patients with high cardiovascular risk were included in this analysis. The study population was separated into 2 groups depending on the occurrence of longterm MACEs. The independent predictors of long-term MACEs in patients with high cardiovascular risk were investigated. The long-term prognostic value of the TyG index in these patients was evaluated in terms of MACEs. Results: Age, male sex, diabetes mellitus, and the TyG index were demonstrated to be independent predictors of long-term MACE occurrence in patients with high cardiovascular risk. The TyG index was independently related to long-term MACEs in patients with high cardiovascular risk (hazard ratio, 1.003; 95% confidence interval [CI], 1.001–1.006; p=0.011). The receiver operating characteristic curve revealed that the optimum value of the TyG index to predict long-term MACEs in the overall study cohort was >9.68, with 65% sensitivity and 63% specificity (area under the curve, 0.71; 95% CI, 0.65–0.77; p<0.001). Conclusion The TyG index was demonstrated to be an independent predictor of long-term MACE occurrence in patients with high cardiovascular risk who had not been previously diagnosed with cardiovascular disease.

Background: Our primary goal was to utilize pulmonary arterial stiffness (PAS) to demonstrate the early alterations in the pulmonary vascular area in individuals with prior COVID-19 illness who had not undergone hospitalization. Methods: In total, 201 patients with prior COVID-19 infection without hospitalization and 195 healthy, age- and sexmatched individuals without a history of COVID-19 disease were included in this prospective analysis. The PAS value for each patient was calculated by dividing the mean peak pulmonary flow velocity by the pulmonary flow acceleration time. Results: The measured PAS was 10.2 ± 4.11 Hz/msec in post–COVID-19 participants and 8.56 ± 1.47 Hz/msec in healthy subjects (P < 0.001). Moreover, pulmonary artery acceleration time was significantly lower in patients with a prior history of COVID-19. Multivariable logistic regression analysis revealed that PAS was significantly connected to a prior COVID-19 illness (odds ratio, 1.267; 95% confidence interval, 1.142–1.434; P < 0.001). The optimal cutoff point for detecting a prior COVID-19 disease for PAS was 10.1 (sensitivity, 70.2%; specificity, 87.7%). Conclusions This might be the first investigation to reveal that patients with a history of COVID-19 had higher PAS values compared to those without COVID-19. The results of the investigation may indicate the need of regular follow up of COVID-19 patients for the development of pulmonary arterial hypertension, especially during the post–COVID-19 interval.

Background: Our primary goal was to utilize pulmonary arterial stiffness (PAS) to demonstrate the early alterations in the pulmonary vascular area in individuals with prior COVID-19 illness who had not undergone hospitalization. Methods: In total, 201 patients with prior COVID-19 infection without hospitalization and 195 healthy, age- and sexmatched individuals without a history of COVID-19 disease were included in this prospective analysis. The PAS value for each patient was calculated by dividing the mean peak pulmonary flow velocity by the pulmonary flow acceleration time. Results: The measured PAS was 10.2 ± 4.11 Hz/msec in post–COVID-19 participants and 8.56 ± 1.47 Hz/msec in healthy subjects (P < 0.001). Moreover, pulmonary artery acceleration time was significantly lower in patients with a prior history of COVID-19. Multivariable logistic regression analysis revealed that PAS was significantly connected to a prior COVID-19 illness (odds ratio, 1.267; 95% confidence interval, 1.142–1.434; P < 0.001). The optimal cutoff point for detecting a prior COVID-19 disease for PAS was 10.1 (sensitivity, 70.2%; specificity, 87.7%). Conclusions This might be the first investigation to reveal that patients with a history of COVID-19 had higher PAS values compared to those without COVID-19. The results of the investigation may indicate the need of regular follow up of COVID-19 patients for the development of pulmonary arterial hypertension, especially during the post–COVID-19 interval.

Background: Our primary goal was to utilize pulmonary arterial stiffness (PAS) to demonstrate the early alterations in the pulmonary vascular area in individuals with prior COVID-19 illness who had not undergone hospitalization. Methods: In total, 201 patients with prior COVID-19 infection without hospitalization and 195 healthy, age- and sexmatched individuals without a history of COVID-19 disease were included in this prospective analysis. The PAS value for each patient was calculated by dividing the mean peak pulmonary flow velocity by the pulmonary flow acceleration time. Results: The measured PAS was 10.2 ± 4.11 Hz/msec in post–COVID-19 participants and 8.56 ± 1.47 Hz/msec in healthy subjects (P < 0.001). Moreover, pulmonary artery acceleration time was significantly lower in patients with a prior history of COVID-19. Multivariable logistic regression analysis revealed that PAS was significantly connected to a prior COVID-19 illness (odds ratio, 1.267; 95% confidence interval, 1.142–1.434; P < 0.001). The optimal cutoff point for detecting a prior COVID-19 disease for PAS was 10.1 (sensitivity, 70.2%; specificity, 87.7%). Conclusions This might be the first investigation to reveal that patients with a history of COVID-19 had higher PAS values compared to those without COVID-19. The results of the investigation may indicate the need of regular follow up of COVID-19 patients for the development of pulmonary arterial hypertension, especially during the post–COVID-19 interval.